Latest Intelligence on Cardiovascular and Diabetes

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

ZymoGenetics: rhThrombin has great potential

In line with the rapid historical uptake of other recombinant protein products, following an anticipated approval in late 2007, ZymoGenetics' rhThrombin is expected to quickly take market share from King Pharmaceutical's Thrombin-JMI. Upon doing so, rhThrombin's revenues are forecast to grow from $165 million in 2008 to an impressive $459 million in 2010, well ahead of Wall Street consensus.

Published By Datamonitor
13 Apr 2006
Expert View
Expert View

Zetia: Potential to reshape the cholesterol drug landscape?

Statins have become the gold standard in the treatment of dyslipidemia, accounting for approximately 60% of treatments prescribed to patients with coronary heart disease in the late 1990s. However, with these drugs limited in their ability to lower LDL cholesterol to the target recommended by the National Institutes of Health an opportunity awaits for a therapy able to achieve this goal.<BR />

Published By Datamonitor
30 May 2003
Expert View
Expert View

Xigris: struggling to overcome its problems

The once lauded drug Xigris is struggling to recover from a series of setbacks, despite existing in a potentially lucrative market with little competition. After disappointing US sales, Xigris has now been launched in Europe. Datamonitor's Michael Randle asks if Eli Lilly can take advantage of its status as the only approved severe sepsis treatment and breathe new life into its sleeping giant.

Published By Datamonitor
15 Nov 2002
Expert View
Expert View

Xarelto data raise questions at the 2010 American Heart Association Scientific Sessions

Results from the ROCKET-AF trial of Xarelto in stroke prevention in atrial fibrillation have been presented at this year's Scientific Sessions of the American Heart Association. While positive, the data show that Xarelto has by no means outperformed Pradaxa. Clinicians may start to see the two drugs as complementary alternatives, based on their respective performance in various subgroups.

Published By Datamonitor
16 Nov 2010
CommentWire
CommentWire

Women's health: more drug trials need the female touch

An analysis of clinical trials investigating drug treatment in cardiovascular disease suggests that too few women are included in study populations. This could lead to risks for women as possible side effects may remain undiscovered. To combat such potential dangers, clinical trial design in heart disease should take gender differences into account.

Published By Datamonitor
04 Aug 2005
CommentWire
CommentWire

Women's health: cardio program takes on the US' biggest killer

Cardiovascular disease is the US' biggest killer of women - but too many believe that diseases such as breast cancer are a greater threat. The new initiative should be a major step in combating the disease through educating and changing behavior. This should benefit both at-risk patients and pharma companies active in the female-specific CVD market.

Published By Datamonitor
04 Feb 2002
CommentWire
CommentWire

Vitamin C: benefits of supplements still in question

Published By Datamonitor
05 Oct 2000
CommentWire
CommentWire

UK health: childhood obesity epidemic feared

A government report published this week reveals that childhood obesity in the UK has tripled in the last 20 years and calls for urgent steps to be taken. The committee is right to advocate the establishment of a high level government committee to tackle obesity, annual BMI tests for children, and a ban on junk food advertising in a bid to address the issue.

Published By Datamonitor
28 May 2004
Expert View
Expert View

UK doctors slow to utilize combination therapy for hypertension

According to new Datamonitor research, the majority of hypertension sufferers are not fully controlled on a single antihypertensive therapy. With many patients requiring a combination of two or three drugs from different classes to adequately lower their blood pressure, not enough doctors are recognizing the importance of multiple drug administration.

Published By Datamonitor
26 Nov 2004
CommentWire
CommentWire

UK cardiovascular disease: statins for all?

Researchers have suggested that in order to tackle heart disease in the country, nearly all middle-aged UK men should receive statins as preventative medicine. This claim points to the great need for new guidelines concerning statin use. However, new guidelines alone might not be enough to combat the prevalence and high cost of cardiovascular disease as more effective measures are required.

Published By Datamonitor
26 May 2006

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.